My ePortfolio Register   

AACR 2014 /
AG-221 shows clinical activity in acute myeloid leukaemia

5th - 9th Apr 2014

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 01.05.14
Views: 1996

Dr Eytan Stein - Memorial Sloan Kettering Cancer Center, New York, USA

Dr Stein talks to ecancertv at the AACR conference about his study of patients with acute myeloid leukaemia who had a mutation in the IDH2 gene. By identifying the substance 2 hydroxyglutarate as an agent which increases levels of leukaemia, they are able to work on lowering the levels which are produced by drawing upon a new cancer metablism drug, AG-221.

Read the article for more.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence